Related Experiment Video
Updated: Oct 10, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.6K
Eplerenone Improves Vascular Endothelial Function in Patients with Primary Aldosteronism: A Pilot Study
Akira Kurozumi1, Yosuke Okada1, Yoshiya Tanaka1
1First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan. Yahatanishi-ku, Kitakyushu 807-8555, Japan.
Journal of UOEH
|December 13, 2021
Summary
Mineralocorticoid receptor antagonists (MRA) improved vascular endothelial function in primary aldosteronism patients. Plasma renin activity (PRA) correlated with improvements and may guide MRA dosing.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Primary aldosteronism (PA) significantly increases cardiovascular disease risk.
- Mineralocorticoid receptor antagonists (MRA) show organ-protective effects in heart failure and myocardial infarction.
- Clinical observations suggest MRA may improve vascular endothelial dysfunction.
Purpose of the Study:
- To evaluate the effect of eplerenone, an MRA, on vascular endothelial function in PA patients.
- To identify factors correlated with changes in vascular endothelial function during MRA therapy.
Main Methods:
- Pilot study involving 10 PA patients treated with eplerenone for 3 months.
- Vascular endothelial function assessed using the Endo-PAT device, measuring the reactive hyperemia index (RHI).
- Correlative analysis performed between RHI changes and other physiological markers.
Main Results:
- The reactive hyperemia index (RHI) significantly increased from 1.71 to 2.21 after 3 months of eplerenone treatment.
- A significant correlation was observed between the change in RHI and the change in plasma renin activity (PRA).
- Plasma aldosterone concentration may increase during MRA therapy, suggesting PRA as a potential dosing marker.
Conclusions:
- Eplerenone treatment significantly improves vascular endothelial function in PA patients.
- Plasma renin activity (PRA) is a potential biomarker for adjusting MRA dosage.
- PRA may serve as a valuable tool for optimizing MRA therapy alongside blood pressure and potassium monitoring.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
558
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
558
01:25Antihypertensive Drugs: Direct Renin Inhibitors
890
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
890
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
1.0K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.0K
01:22Heart Failure Drugs: Diuretics
523
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
523
01:30Heart Failure V: Medical Management
46
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
46
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
238
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
238